Hua Medicine Completes Phase II Trial of Type 2 Diabetes Drug

Hua Medicine of Shanghai reports it has successfully completed a Phase II trial of HMS5552, a novel fourth-generation oral Glucokinase Activator (GKA) for type 2 diabetes. Hua in-licensed global rights to the candidate from Roche in 2011, its first program. The proof-of-concept trial, which enrolled 258 patients in 22 hospital centers across China, was led by Professor Dalong Zhu, President-elect of the Chinese Diabetes Society. Hua will release topline safety and efficacy results by mid-October. More details.... Stock Symbol: (SIX: ROG) Share this with colleagues: // //